GlassScriptPhysician profile
Monika D Vasic
NPI 1275935132
$24,879.38
in general payments reported to CMS, 2019-2025
63 companies · $6,314 in 2025
The $6,314 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,797 · 2022: $3,542 · 2023: $6,075 · 2024: $6,152 · 2025: $6,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,357.62 |
| Education | $183.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,853.34 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,954.29 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $2,953.18 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $2,458.61 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $844.65 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $799.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $716.45 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $673.17 | 2022-2025 | Linzess |
| Celgene Corporation | $599.49 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $507.65 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $449.26 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $442.40 | 2021-2025 | Nucala |
| Jazz Pharmaceuticals INC. | $429.26 | 2021-2022 | |
| Genzyme Corporation | $420.69 | 2021-2025 | |
| Qol Medical, LLC | $395.47 | 2023-2025 | Sucraid |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monika Vasic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.